PLXNA1 and myeloid sarcoma: Hence, because current treatments of MS are essentially combating inflammation but are not repairing lesions, future studies will address whether a combination treatment associating anti‐inflammatory molecules with Plexin‐A1 antagonist creates all conditions for repairing MS lesions.